Nocardia

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023

Retrieved on: 
Monday, June 12, 2023
Post-exposure prophylaxis, Public, Infection, George R. Brown Convention Center, ASM, Brain, Government, Immunodeficiency, Gram-positive bacteria, Skin, Vaccine, Paint, Nocardia

BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA® (omadacycline) will be presented at ASM Microbe 2023 conference.

Key Points: 
  • BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA® (omadacycline) will be presented at ASM Microbe 2023 conference.
  • The hybrid conference will be held June 15-19 at the George R. Brown Convention Center in Houston, TX.
  • View ASM Microbe scientific program here .
  • “Presentations at ASM Microbe provide data from two key studies that further explore the potential of NUZYRA as an option for the treatment and post-exposure prophylaxis in the event of an anthrax bioterror attack,” said Randy Brenner, chief development and regulatory officer of Paratek.

Karius® Partners with Capstone Health Alliance to Widen Patient Access to Liquid Biopsy Test for Infectious Diseases

Retrieved on: 
Thursday, June 9, 2022
Society, Liquid biopsy, Infection, GenomeWeb, Plasma, Aggregation, Partnership, Awareness, Organization, Multimedia, Bed, Patient, Hospital, DNA, Health, Diagnosis, Twitter, MD, View, Leptospira, Pharmaceutical industry, Vaccine, The New York Times, Loris Karius, Nocardia, Capstone

REDWOOD CITY, Calif., June 9, 2022 /PRNewswire/ -- Karius®, the world leader in liquid biopsy for infectious diseases, today announced a partnership with Capstone Health Alliance, a group purchasing organization focused on supply chain savings in hospitals and other organizations, to streamline patient access to the Karius Test®. The Karius Test is a lab-developed test that can non-invasively and rapidly detect more than 1,000 pathogens throughout the body from a single blood sample. Through the partnership, doctors at over 265 Capstone member hospitals across the U.S. can now more easily order the Karius Test for patients harboring hard-to-diagnose infections.

Key Points: 
  • REDWOOD CITY, Calif., June 9, 2022 /PRNewswire/ -- Karius , the world leader in liquid biopsy for infectious diseases, today announced a partnership with Capstone Health Alliance, a group purchasing organization focused on supply chain savings in hospitals and other organizations, to streamline patient access to the Karius Test.
  • The Karius Test is a lab-developed test that can non-invasively and rapidly detect more than 1,000 pathogens throughout the body from a single blood sample.
  • Capstone and Karius are focused on expanding access to quality medical care especially for patients at high risk, such as those with compromised immune systems.
  • "We are thrilled to partner with Capstone Health Alliance to accelerate access for patients to our metagenomic infectious disease test," said Brad Perkins, MD, Chief Medical Officer of Karius.